Prognostic implications of predialysis patients’ symptoms in peritoneal dialysis patients

Fang-Yu Wang*, Zhan Cui*, Chun-yan Su, Tao Wang and Wen Tang

Department of Nephrology, Peking University Third Hospital, Beijing, China

ABSTRACT

Background: As kidney disease progresses, patients often experience a variety of symptoms. There are very few studies reporting spectrum of predialysis patients’ symptoms in peritoneal dialysis (PD) patients. Furthermore, the clinical significance of predialysis patients’ symptoms for PD patients’ prognosis remains unknown.

Methods: In this retrospective cohort study, patients who started PD during 1 January 2006 to 31 January 2018 were included. Patients’ predialysis symptoms and clinical parameters were obtained. Both the short- and long-term patients’ outcome were investigated by Cox regression and Kaplan–Meier’s survival analysis to identify the relationship between clinical symptoms and patients’ mortality on PD.

Results: A total of 898 incident PD patients were included. The anorexia (58%) was the most common predialysis symptom in the present cohort, followed by insomnia (32.7%), fatigue (27.6%), syndromes of heart failure (27.6%), and nausea (20.5%). The only symptom significantly associated with both six-months and 12-months mortality on PD was nausea (HR 2.359, 95% CI 1.377–4.040, p = .002 and HR 1.791, 95% CI 1.176–2.729, p = .007, respectively). But in the long-term, anorexia (HR 1.392, 95% CI 1.070–1.811, p = .014) was the only symptom significantly associated with patient’s all-cause mortality after adjusting for other confounding factors.

Conclusions: Our study demonstrated that nausea and anorexia were the most important predialysis symptoms, which was associated with patients’ short- and long-term mortality on PD treatment, respectively. The results indicated that predialysis evaluation and management of symptoms of nausea and anorexia may be a possible way to improve patients’ outcome on PD.

Abbreviations: PD: peritoneal dialysis; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration creatinine equation; IQR: interquartile range; HD: hemodialysis; PEW: protein-energy wasting

Background

As kidney disease progresses, patients often experience a variety of symptoms [1,2], such as anorexia, fatigue, cognitive impairment, depressive symptoms, pruritus, and sleep disturbances [3]. As showed by the IDEAL study [4] that 76% of the patients allotted to late dialysis had to start dialysis before the target of estimated glomerular filtration rate (eGFR) <7 ml/min due to uremic symptoms. These further supported the notion that the predialysis symptoms are crucial in clinic setting for clinician to decide the right timing to begin dialysis [4,5].

To identify the most meaningful symptoms and accordingly, to decide the right timing of dialysis initiation is still a challenge for the nephrologists. However, there are very few studies reporting spectrum of predialysis patients’ symptoms in peritoneal dialysis (PD) patients and little is known about the burden of symptoms of predialysis patients especially PD patients [6]. In addition, unlike many predialysis indicators linking to the patients outcomes, such as GFR, serum albumin [7,8], calcium [9,10], body mass index [11], and comorbidities [8,12], the potential predictive value of patients’ predialysis symptoms have not been fully elucidated.

In the present study, we investigated spectrum of predialysis symptoms and tried to identify the most important predialysis symptoms linking to patients’ short-term and long-term outcomes.
Methods
In this retrospective cohort study, all incident patients who started PD therapy from 1 January 2006 to 31 January 2018 from Peking University Third Hospital were included. Patients were excluded if they had received any form of dialysis for more than 1 month, or if they had received previous kidney transplantation. Patients who started PD in other center were also excluded for we were unable to get their detailed predialysis symptom information. All the patients were followed by PD clinic of Peking University Third Hospital. Patients were followed until death, cessation of PD or end of study as of 15 November 2018. Patients’ medical charts were reviewed to extract the information. In our center, predialysis patients need to be hospitalized to department of nephrology for performing PD catheter implantation. Therefore, patients’ detailed predialysis clinic symptoms, predialysis manifestations, clinical history, demographics, lab assay were recorded when admitted. During the study period, patients’ hospitalization medical charts were carefully reviewed to obtain the predialysis symptom data.

The study protocol was approved by the Peking University Third Hospital Medical Science Research Ethics Committee, IRB00006761-M2019290. Review of patients’ records and use of data by this study were permitted by Peking University Third Hospital Medical Science Research Ethics Committee. Patients’ eGFR was estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation [13]. Hypocalcemia were defined as fasting plasma calcium level lower than 2.0 mmol/l and hyperphosphatemia were defined as fasting plasma phosphorus level higher than 1.78 mmol/l. The primary outcomes examined were all-cause mortality on PD (censored for loss to follow-up, renal transplantation, recovery of renal function, transferred to hemodialysis (HD) due to technical failure, transfer to other dialysis centers and end of study).

Statistical analysis
Results were expressed as frequencies and percentages for categorical variables, mean ± standard deviation for continuous normally distributed variables, and median (interquartile range, IQR) for continuous variables that were not normally distributed. Comparison for patients in different groups was performed using chi-square tests, two-tailed unpaired t-tests or Mann–Whitney’s tests, depending on data distribution. Mortality risks (both 0.5, 1 year and long-term mortality) were analyzed by the Kaplan–Meier and multivariate Cox’s proportional hazard model in which all the significant variables (p<.1) from the univariate analysis were included. Statistical analysis was performed using IBM SPSS software, version 22.0 (Armonk, NY). p Values less than .05 were considered statistically significant.

Results
Clinical and laboratory characteristics at the initiation of PD are depicted in Table 1. Patients’ uremic manifestations and syndromes at the initiation of PD are shown in Figure 1. The anorexia (58%) was the most common symptom in the present cohort, followed by insomnia (32.7%), fatigue (27.6%), syndromes of heart failure (27.6%), and nausea (20.5%), respectively.

All the patients were followed until 15 November 2018. A total of 898 incident PD patients with a median follow-up of 3.73 (inter-quarter range 1.13, 5.56) years were included in the present study. Death occurred in 384 (42.8%) patients. The causes of death were cardiovascular disease (38%), peritonitis (6.5%), multiple organ failure (9.6%), infection (14.1%), tumor (6.8%), gastrointestinal bleeding (6.5%), respiratory failure (6%), withdraw of therapy (4.4%), and unknown reasons (8.1%).

| Table 1. Clinical and laboratory characteristics at the time of peritoneal dialysis initiation in 898 patients with CKD. |
|---------------------------------|-----------------|----------------|
|                                 | Mean ± SD       | Median (IQR)   |
| **Patients characteristics**    |                 |                |
| Age (years)                     | 59.55 ± 16.34   | 61.31 [48.98–72.49] |
| Males (%)                       | 50.9            |                |
| Height (cm)                     | 163.6 ± 8.4     | 163.0 [157.0–170.0] |
| Weight (kg)                     | 62.8 ± 12.7     | 62.0 [54.0–71.0] |
| BMI (kg/m²)                     | 23.4 ± 3.8      | 23.1 [20.8–25.6] |
| **Laboratory parameters**       |                 |                |
| Creatinine (µmol/l)             | 803 ± 345       | 734 [570–966] |
| Urea (mmol/l)                   | 29.5 ± 10.5     | 28.9 [22.3–35.3] |
| Albumin (g/l)                   | 35.5 ± 5.4      | 36.0 [31.8–39.6] |
| Hemoglobin (g/l)                | 85.1 ± 19.2     | 84.0 [72.0–98.0] |
| Calcium (mmol/l)                | 1.96 ± 0.31     | 1.98 [1.80–2.14] |
| Phosphate (mmol/l)              | 1.94 ± 0.59     | 1.98 [1.51–2.31] |
| Parathyroid hormone (pg/ml)     | 307 ± 259       | 245 [138–417]  |
| Urine volume (ml)               | 1065 ± 583      | 1000 [650–1401] |
| eGFR (ml/min.1.73 m²)           | 6.08 ± 3.13     | 5.33 [4.02–7.42] |
| **Comorbidities**               |                 |                |
| Acute heart failure             | 27.6            |                |
| Pulmonary infection             | 12.5            |                |
| Diabetes mellitus               | 38.3            |                |
| Coronary heart disease          | 19.3            |                |
| Old myocardial infarction       | 5.8             |                |
| Cerebral infarction             | 11.9            |                |
| Cerebral hemorrhage             | 2.4             |                |
| Amputation                      | 0.4             |                |
| Uremia encephalopathy           | 0.7             |                |
| Hyperkalemia                    | 7.5             |                |
| Acidosis                        | 52.2            |                |
| Hypocalcemia                    | 48.7            |                |
| Hyperphosphatemia               | 48.3            |                |
| Hypertension                    | 94.1            |                |

CKD: chronic kidney disease; CI: confidence interval; BMI: body mass index; eGFR: estimated glomerular filtration rate. Acidosis is defined as CO2CP <23 mmol/l; hyperkalemia is defined as potassium >5.5 mmol/l; hypocalcemia is defined as serum calcium level <2.00; hyperphosphatemia is defined as serum phosphorus >1.78 mmol/l.
A total of 28 patients (3.1%) transferred to HD. Fifty-one patients (5.6%) underwent renal transplantation and five patients (0.5%) had recovery of renal function during follow-up. Loss to follow-up occurred in six patients (0.6%) and 20 patients (2.2%) transferred to other dialysis centers.

Patients’ symptoms and short-term outcome on PD
Both the six-months and 12-month mortality were evaluated in the present study for patients’ short-term outcome. Univariate Cox regression analysis showed that the only symptom significantly associated with both six-months and 12-months mortality on PD was nausea (HR 2.359, 95% CI 1.377–4.040, *p* = .002 and HR 1.791, 95% CI 1.176–2.729, *p* = .007, respectively) (Table 2).

Both the six-months and 12-month survival time of patients with symptom of nausea were significantly lower compared to patients without (log rank test, both *p* < .001) (Figure 2). Multivariate Cox regression analysis showed symptoms of nausea (HR 2.282, 95% CI 1.085–4.797, *p* = .030) was significantly associated with patient’s all-cause mortality in six month after adjusting for age (HR 2.282, 95% CI 1.085–4.797, *p* = .030) was significantly associated with patient’s all-cause mortality in six month after adjusting for age (HR 1.070, 95% CI 1.034–1.107, *p* < .001), serum albumin (HR 0.878, 95% CI 0.814–0.947, *p* = .001), urine volume (HR 0.999, 95% CI 0.998–1.000, *p* = .044), and other confounding factors. Similarly, multivariate Cox regression analysis showed symptoms of nausea (HR 2.004, 95% CI 1.180–3.402, *p* = .010) was significantly associated with patient’s all-cause mortality in 12 months after adjusting for age (HR 1.055, 95% CI 1.032–1.079, *p* < .001), serum albumin (HR 0.902, 95% CI 0.856–0.950, *p* < .001), urine volume (HR 0.999, 95% CI 0.998–1.000, *p* < .001), with cerebral hemorrhage (HR 5.303, 95% CI 1.813–15.508, *p* = .002) and other confounding factors.

Patients’ symptoms and long-term mortality on PD
Univariate Cox regression analysis showed that the predialysis symptoms significantly associated with patients’ all-cause mortality were dyspnea (*p* = .001), edema (*p* = .016), nausea (*p* = .033), anorexia (*p* < .001), and insomnia (*p* = .008) (Table 3). Interestingly, multivariate Cox regression analysis showed that anorexia (HR 1.392, 95% CI 1.070–1.811, *p* = .014) was the only symptom significantly associated with patients’ all-cause mortality after adjusting for other confounding factors (Table 3). The survival time of patients with symptom of anorexia was significantly lower compared to patients who without anorexia (log rank test, *p* < .001) (Figure 3).

Discussion
In this retrospective cohort study, we found that the most common predialysis symptom was anorexia. Most importantly, we demonstrated that predialysis anorexia
Table 2. Cox regression model with predialysis patients’ symptoms included to investigate predictors for short-term mortality for patients underwent peritoneal dialysis.

| Variable                  | Six months mortality | One year mortality |
|---------------------------|----------------------|-------------------|
|                           | Univariate Cox       | Multivariate Cox  | Univariate Cox       | Multivariate Cox  |
|                           | HR [95% CI] p        | HR [95% CI] p     | HR [95% CI] p        | HR [95% CI] p     |
| Patients characteristics  |                      |                   |                      |                   |
| Age (per 1-year increase) | 1.046 [1.025–1.067]  | <.001             | 1.070 [1.034–1.107]  | <.001             |
| Gender (male)             | 1.430 [0.845–2.419]  | .183              | 1.288 [0.873–1.900]  | .201              |
| BMI (kg/m²)               | 0.884 [0.816–0.958]  | .002              | 0.939 [0.845–1.044]  | .247              |
| Laboratory parameters    |                      |                   |                      |                   |
| Creatinine (per 1-µmol/l increase) | 0.999 [0.998–1.000] | .355             | 1.000 [0.999–1.001] | .955              |
| Albumin (per 1-g/l increase) | 0.876 [0.835–0.919]  | <.001             | 0.878 [0.814–0.947]  | <.001             |
| Hemoglobin (per 1-g/l increase) | 1.006 [1.000–1.012] | .354             | 1.006 [0.996–1.016]  | .240              |
| Calcium (per 1-mmol/l increase) | 2.176 [0.943–5.019] | .088             | 2.386 [0.649–8.780]  | .191              |
| Parathyroid hormone (per 1-pg/ml increase) | 0.998 [0.996–0.999] | .011             | 1.000 [0.998–1.002]  | .981              |
| eGFR (per 1-ml/min.1.73 m² increase) | 1.045 [0.975–1.120] | .217             | 1.057 [1.003–1.113]  | .038              |
| Acidity                   | 1.168 [0.692–1.970]  | .561              | 0.772 [0.338–1.760]  | .538              |
| Comorbidities             |                      |                   |                      |                   |
| Acute heart failure       | 1.215 [0.695–2.124]  | .494              | 1.350 [0.898–2.029]  | .149              |
| Pulmonary infection       | 1.199 [0.568–2.531]  | .634              | 1.890 [1.170–3.052]  | .009              |
| Diabetes mellitus         | 1.153 [0.681–1.950]  | .596              | 1.510 [1.026–2.222]  | .037              |
| Coronary heart disease    | 1.469 [0.814–2.648]  | .201              | 1.320 [0.841–2.071]  | .227              |
| Old myocardial infarction | 1.987 [0.853–4.629]  | .112              | 1.852 [0.964–3.555]  | .064              |
| Cerebral infarction       | 1.582 [0.800–3.131]  | .186              | 1.488 [0.884–2.503]  | .134              |
| Cerebral hemorrhage       | 2.186 [0.684–6.992]  | .187              | 2.529 [1.109–5.769]  | .027              |
| Predialysis symptoms      |                      |                   |                      |                   |
| Dyspnea                   | 1.564 [0.768–3.188]  | .218              | 1.447 [0.837–2.502]  | .186              |
| Hypertension              | 0.282 [0.143–0.559]  | <.001             | 0.776 [0.229–2.631]  | .684              |
| Pericarditis              | 2.149 [0.672–6.874]  | .197              | 1.983 [0.807–4.871]  | .135              |
| Edema                     | 1.006 [0.364–2.780]  | .991              | 1.431 [0.746–2.748]  | .281              |
| Fatigue                   | 1.456 [0.845–2.509]  | .176              | 1.329 [0.881–2.003]  | .175              |
| Anorexia                  | 1.258 [0.722–2.147]  | .410              | 1.307 [0.874–1.955]  | .192              |
| Nausea                    | 2.359 [1.377–4.040]  | .002              | 2.282 [1.085–4.797]  | .030              |
| Weight loss               | 1.102 [0.541–2.245]  | .790              | 0.846 [0.473–1.513]  | .573              |
| Pruritus                  | 0.419 [0.058–0.326]  | .388              | 1.480 [0.649–3.375]  | .352              |
| Insomnia                  | 0.609 [0.366–1.222]  | .191              | 1.010 [0.670–1.522]  | .963              |
| Diarrhea                  | 1.422 [0.444–4.547]  | .553              | 1.683 [0.738–3.840]  | .216              |

Kaplan-Meier Survival Estimates

![Kaplan-Meier Survival Estimates](image)

Nausea Group
- without nausea
- with nausea

At risk
- without nausea 714 670 639 623 601 564
- with nausea 184 167 153 143 140 132

Figure 2. Kaplan–Meier’s one-year survival curve for peritoneal dialysis patients with or without predialysis symptom of nausea.
was a strong and significant predictor for PD patients’ long-term mortality. In addition, presenting with symptom of nausea was associated with high short-term PD mortality after adjusting for all the other confounding factors.

Anorexia (58%) was the most common symptom in the present cohort, followed by insomnia (32.7%), fatigue (27.6%), syndromes of heart failure (27.6%), and nausea (20.5%). These results are different from the previous study that the most common symptoms were fatigue (44%), nausea (24%), and anorexia (22%) at the dialysis initiation [6]. Nausea and anorexia are major uremic symptoms and a frequent indication for starting dialysis [14]. The higher present of anorexia and nausea may reflect a relatively late start of dialysis in the present predialysis patients. Interestingly, we found that nausea is a more powerful predictor for patients’ short-term (6 and 12 months) mortality than anorexia after adjusting other confounding factors, which indicated that for patients with symptoms of nausea, more intensive treatment may be needed to ameliorate the symptom and thus to improve patients short-term outcome.

 Previous study in PD patients showed that self-reported appetite (anorexia) was a predictor of clinical characteristics and outcome for patients receiving PD [15] and HD patients [16]. Different from this study which anorexia were evaluated on PD at least 12 weeks or on HD for at least 120 days [16], symptom of anorexia was evaluated just before PD initiation in the present study. The symptoms of anorexia in the present study reflect predialysis patients’ status rather than after dialysis, which may indicate that in advance chronic kidney disease (CKD), the symptoms of anorexia could be an indicator of long-term PD outcomes in spite that standard dialysis prescription was delivered. This result is consistent with the study from Thiane et al. who showed that in CKDS non-dialysis patients, there was a

| Variable | Univariate Cox regression | Multivariate Cox regression |
|----------|--------------------------|---------------------------|
| HR [95% CI] | p | HR [95% CI] | p |
| **Patient characteristics** | | | |
| Age (per 1-year increase) | 1.050 [1.042–1.059] | <.001 | 1.051 [1.040–1.063] | <.001 |
| Gender (male) | 0.987 [0.880–1.206] | .901 | 0.958 [0.932–0.985] | .003 |
| BMI (kg/m²) | 0.958 [0.932–0.985] | .003 | 0.984 [0.952–1.018] | .354 |
| **Laboratory parameters** | | | |
| Creatinine (per 1-μmol/l increase) | 0.999 [0.998–0.999] | <.001 | 1.000 [0.999–1.001] | .629 |
| Urea (per 1-mmol/l increase) | 0.979 [0.969–0.989] | <.001 | 1.004 [0.988–1.020] | .602 |
| Albunin (per 1-g/l increase) | 0.944 [0.926–0.962] | <.001 | 0.951 [0.927–0.976] | .200 |
| Hemoglobin (per 1-g/l increase) | 0.999 [1.000–1.010] | .064 | 1.000 [0.999–1.006] | .975 |
| Calcium (per 1-mmol/l increase) | 1.963 [1.445–2.667] | <.001 | 2.647 [1.713–4.092] | <.001 |
| Phosphorus (per 1-mmol/l increase) | 0.655 [0.542–0.791] | <.001 | 1.024 [0.783–1.338] | .864 |
| Parathyroid hormone (per 1-pg/ml increase) | 0.999 [0.998–0.999] | <.001 | 1.000 [0.999–1.001] | .879 |
| Urine volume (ml) | 0.999 [0.999–1.000] | <.001 | 1.000 [0.999–1.000] | .002 |
| eGFR (per 1-ml/min.1.73 m² increase) | 1.077 [1.048–1.107] | <.001 | 1.005 [0.942–1.072] | .884 |
| Hyperkalemia | 1.231 [0.861–1.759] | .234 | 0.889 [0.727–1.087] | .251 |
| Acidosis | 0.889 [0.727–1.087] | .251 | | |
| **Comorbidities** | | | |
| Acute heart failure | 1.352 [1.095–1.669] | .005 | 1.226 [0.919–1.635] | .166 |
| Pulmonary infection | 1.448 [1.098–1.908] | .009 | 1.097 [0.788–1.527] | .583 |
| Diabetes mellitus | 1.725 [1.410–2.110] | <.001 | 1.344 [1.041–1.736] | .023 |
| Coronary heart disease | 1.772 [1.614–2.219] | <.001 | 0.925 [0.672–1.274] | .634 |
| Old myocardial infarction | 2.030 [1.419–2.904] | <.001 | 1.247 [0.773–2.013] | .366 |
| Cerebral infarction | 1.388 [1.042–1.848] | .025 | | |
| Cerebral hemorrhage | 1.458 [0.838–2.536] | .182 | | |
| **Predialysis symptoms** | | | |
| Dyspnea | 1.664 [1.238–2.236] | .001 | 1.241 [0.844–1.827] | .273 |
| Hypertension | 0.720 [0.502–1.072] | .11 | | |
| Pericarditis | 1.013 [0.541–1.899] | .967 | | |
| Edema | 1.507 [1.078–2.106] | .016 | 1.083 [0.710–1.651] | .713 |
| Fatigue | 1.190 [0.958–1.478] | .116 | | |
| Anorexia | 1.455 [1.181–1.792] | <.001 | 1.392 [1.070–1.811] | .014 |
| Nausea | 1.289 [1.021–1.627] | .033 | 1.204 [0.905–1.602] | .202 |
| Weight loss | 0.913 [0.677–1.233] | .554 | | |
| Pruritus | 1.523 [0.948–2.446] | .082 | 1.186 [0.678–2.076] | .500 |
| Insomnia | 1.328 [1.078–1.637] | .008 | 0.999 [0.771–1.295] | .995 |
| Diarrhea | 1.115 [0.665–1.869] | .681 | | |

CI: confidence interval; BMI: body mass index; eGFR: estimated glomerular filtration rate. Multivariate Cox regression model included all the significant variables (p<.1) from the univariate analysis. Acidosis is defined as CO2CP <5.5 mmol/l; hyperkalemia is defined as potassium >5.5 mmol/l.
significant increase in mortality risk in PD patients with poor appetite [16]. The underlining causes for anorexia could be accumulation of unidentified anorexigenic compounds, inflammatory cytokines, and alterations in appetite regulation [17,18]. This further contributes to the high prevalence of protein-energy wasting (PEW) and could have a direct adverse effect on morbidity and mortality of these patients [13].

Our study suggest that a single evaluation of predialysis symptoms of anorexia can help identify patients with high risk after PD, which suggested performing appetite evaluation periodically is crucial for patients with advance CKD and may help to decide the right timing for commencing maintenance dialysis treatment. Therefore, more intensive intervention and management either before or after PD treatment would be necessary for these patients. Further study is needed to elucidate the possible effect of appetite improvement by PD as well as its effect on clinical outcomes.

Our study has some limitations. First, patients included in this study were recruited from a single tertiary academic hospital in China, thereby raising the possibility of ascertainment bias. Second, due to the retrospective design, some detailed symptoms severity could not be obtained. Finally, although we attempted to adjust for a range of demographic, clinical, and laboratory characteristics, some detailed comorbidity index (e.g., Charlson comorbidity index and nutritional status assessment like subjective global nutrition assessment, SGA) was not collected, thus residual confounding remains possible.

**Conclusions**

Our study demonstrated that predialysis nausea and anorexia were the most important predialysis symptoms, which was associated with patients’ short-term and long-term mortality on PD treatment, respectively. These results indicated that predialysis evaluation and management of symptoms of nausea and anorexia may be a possible way to improve patients’ outcome on PD.

**Acknowledgements**

*Ethics approval and consent to participate:* The study protocol was approved by the Peking University Third Hospital Medical Science Research Ethics Committee, IRB00006761-M2019290. In all cases, a waiver for informed consent was granted due to the observational nature of the study and patient records and information were anonymized and de-identified prior to analysis.

**Disclosure statement**

The authors declare that they have no competing interests.
Funding
This work was supported by grants from Peking University Medicine Seed Fund for Interdisciplinary Research (BMU2020MI010), the National Natural Science Foundation of China (Project No. 30900681) and the Chinese Society of Nephrology (No. 1405046058).

Data availability statement
The datasets used during the current study are available from the corresponding author on reasonable request.

References
[1] Kestenbaum B, Seliger SL. Commentary on symptom management of the patient with CKD: the role of dialysis. Clin J Am Soc Nephrol. 2017;12(4):694–695.
[2] Almutary H, Bonner A, Douglas C. Which patients with chronic kidney disease have the greatest symptom burden? A comparative study of advanced CKD stage and dialysis modality. J Ren Care. 2016;42(2):73–82.
[3] de Mutsert R, Grootendorst DC, Axelsson J, et al. Group tNS: excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant. 2008;23(9):2957–2964.
[4] Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609–619.
[5] Tattersall J, Dekker F, Heimburger O, et al. When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant. 2011;26(7):2082–2086.
[6] Heaf J, Petersons A, Vernere B, et al. Why do physicians prescribe dialysis? A prospective questionnaire study. PLoS One. 2017;12(12):e0188309.
[7] Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol. 1996;7(2):198.
[8] Hoffman W, Sheth H, Bender F, et al. Outcomes of PD patients at 6 months. Perit Dial Int. 2017;37(1):116–118.
[9] Matsu M, Akai Y, Samejima KI, et al. Prognostic value of predialysis indices for technique failure and mortality in peritoneal dialysis patients. Ther Apher Dial. 2017;21(5):493–499.
[10] Tang W, Hu XH, Zhu L, et al. Pre-dialysis renal clinic visits and patients’ outcomes on peritoneal dialysis. Int Urol Nephrol. 2016;48(11):1–7.
[11] Obi Y, Streja E, Mehrotra R, et al. Impact of obesity on modality longevity, residual kidney function, peritonitis, and survival among incident peritoneal dialysis patients. Am J Kidney Dis. 2018;71(6):802–813.
[12] Kishida K, Maruyama Y, Asari K, et al. Clinical outcome of incident peritoneal dialysis patients with diabetic kidney disease. Clin Exp Nephrol. 2019;23(3):409–414.
[13] Levey A, Stevens L, Schmid C, et al. A new equation to estimate glomerular filtration rate (vol 150, pg 604, 2009). Ann Intern Med. 2011;155:408–408.
[14] Huang B, Zhou Z, Xu H, et al. Diminished appetite predicts mortality of Chinese peritoneal dialysis patients. Biol Res Nurs. 2014;16(3):241–249.
[15] Lopes AA, Elder SJ, Ginsberg N, et al. Lack of appetite in haemodialysis patients—associations with patient characteristics, indicators of nutritional status and outcomes in the international DOPPS. Nephrol Dial Transplant. 2007;22(12):3538–3546.
[16] Thiane GA, Bengt L, Peter B, et al. Self-rated appetite as a predictor of mortality in patients with stage 5 chronic kidney disease. J Renal Nutr. 2013;23(2):106–113.
[17] Chazot C. Why are chronic kidney disease patients anorexic and what can be done about it? Semin Nephrol. 2009;29(1):15–23.
[18] Reid J, Noble HR, Adamson G, et al. Establishing a clinical phenotype for cachexia in end stage kidney disease – study protocol. BMC Nephrol. 2018;19(1):38.